Pages that link to "Q54157736"
Jump to navigation
Jump to search
The following pages link to Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous in (Q54157736):
Displaying 10 items.
- A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation (Q28345464) (← links)
- A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration (Q30321809) (← links)
- Clinical and preclinical pharmacokinetics of raltitrexed. (Q30653901) (← links)
- Pharmacodynamic modelling of biomarker data in oncology (Q34241935) (← links)
- Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. (Q36024905) (← links)
- From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates (Q36354734) (← links)
- Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel (Q36621462) (← links)
- Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics (Q36640945) (← links)
- Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. (Q43236564) (← links)
- Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma (Q80224586) (← links)